Quest Diagnostics (NYSE:DGX) reported robust financial results for the first quarter of 2026, characterized by high-single-digit organic revenue growth and a double-digit increase in earnings.
The company’s performance reflects a sustained demand for base laboratory testing and the successful integration of recent acquisitions, leading management to raise its full-year profitability outlook.
For the quarter ended March 31, 2026, the Secaucus, New Jersey-based provider posted revenues of $2.90 billion, representing a 9.2% increase over the same period in 2025.
Growth was almost entirely organic, with organic revenue rising 9%, signaling a strong volume recovery and a favorable shift in the company’s test mix toward more advanced diagnostics.
Profitability metrics saw significant improvement year-over-year.
Reported diluted earnings per share (EPS) rose 15.5% to $2.24.
On an adjusted basis—which excludes specific amortization and restructuring costs—diluted EPS reached $2.50, a 13.1% increase compared to the first quarter of 2025.
The results were driven by the company's "Invigorate" cost-management program and higher operating leverage from increased testing volumes.
Following the strong start to the year, Quest Diagnostics updated its financial targets for the remainder of 2026.
The company now expects full-year reported diluted EPS to fall between $9.58 and $9.78.
Adjusted diluted EPS guidance was raised to a range of $10.63 to $10.83, up from previous projections, as the firm anticipates continued momentum in its physician and hospital laboratory services.